Articles by Manali Kamdar, MD
Manali Kamdar, MD, assesses the effect on clinical practice from these label updates for CD19- and BCMA-targeting therapies.
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.